Nxera Pharma said it received a $10 million milestone payment from AbbVie after hitting its 4th R&D milestone under a multi-target neurological diseases collaboration. The update is a positive though incremental funding/validation signal for Nxera’s biotech pipeline progress.
Nxera Pharma said it received a $10 million milestone payment from AbbVie after hitting its 4th R&D milestone under a multi-target neurological diseases collaboration. The update is a positive though incremental funding/validation signal for Nxera’s biotech pipeline progress.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
